Heading to #AACR24? Connect with John Mulligan, Ph.D., Diane Hollenbaugh, Ph.D., Justin Killebrew, Ph.D., & Shannon Okada as they share preclinical data for the first time on our lead program, cLag3-IL2, demonstrating the power of Bonum’s technology platform. Don’t miss Bonum's poster on our conditionally active therapeutic that targets IL-2 to LAG3 cells while remaining systemically inert, even at high treatment doses. Abstract Number: 4062 Date/Time: Tuesday, April 9, 2024 - 9:00 AM - 12:30 PM Session Title: Immune Modulation with Cytokines For more information: https://ow.ly/ZkQA50R7Xme
Bonum Therapeutics’ Post
More Relevant Posts
-
I feel on cloud nine to announce the publication of our article entitled “Selective Inhibition of indoleamine and tryptophan 2,3-dioxygenases: Comparative Study on Kynurenine Pathway in Cell Lines via LC-MS/MS-based Targeted Metabolomics” available under open access licence for everyone who may be interested in. 😄 Here you may find the direct link: https://lnkd.in/gyutZR78 It concerns a validated LC-MS/MS method to quantify the “kynurenines”, which are the major tryptophan catabolites, in cellular supernatants. Our method was successfully applied to assess the in vitro potency of IDO1 selective inhibitors in early drug discovery phases and to obtain vital information about our cell models (A375, U87, MDA-MB-231 cell lines). All the obtained info will be exploited to support the biological characterization of novel inhibitors targetting IDO or TDO. Hence, it is not the end of our journey definetely. 🔬 #LCMS #KynureninePathway #IDO #TDO #TargetedMetabolomics Undoubtedly the support and collaboration provided by Professors Silvia Fallarini, Silvio Aprile, and Tracey Pirali were crucial for the success of this paper, thank you very much. 🤝 I leap at the occasion to sincerely thank Sarah Jane Rezzi, and Rita Maria Concetta Di Martino for the active collaboration and support, I appreciated it heartly. 😊 Last but not the least, I give my heartfelt acknowledgements to Professor Erika Del Grosso for her fundamental guidance without which it couldn’t be possible. 🤗 I know this is just the beginning of my journey as a scientist, but I will never give up; looking straight forward for the self-improvement. Thank you to everyone who has been or will be part of this journey! 🤞
Selective inhibition of indoleamine and tryptophan 2,3-dioxygenases: Comparative study on kynurenine pathway in cell lines via LC-MS/MS-based targeted metabolomics
sciencedirect.com
To view or add a comment, sign in
-
One of the most important aspects of this is the up-and-coming platform to deal with patients with thyroid disease. As Cynthia and I discussed in our recent interview (see https://lnkd.in/ezdTkQAW) it could actually supplant T1D near-term as Sernova's most important and monetarily lucrative application.
🧬Chief Executive Officer at Sernova | Board Member in Biotech, Advanced Therapies, Precision Medicine & Pharmaceuticals
Today we filed our fiscal year end financials with SEDAR and shared a summary of key 2023 accomplishments, including positive T1D clinical results, along with select 2024 milestones (it's going to be an exciting year for Sernova!): 📈 Additional data from Cohort 2 of the ongoing U.S. Phase 1/2 clinical trial, which is evaluating its enhanced 10-channel Cell Pouch in patients with T1D, are expected beginning in Q1. ⚕️Additional preclinical data to support an IND application to evaluate the Company’s autograft thyroid cells in patients suffering from thyroid disease, with no immunosuppressive regimen required. 🤝 Potential engagement with additional life sciences focused companies, academic institutions and external parties through partnership and collaboration opportunities, which could be announced over the course of 2024. 💰 Additional funding to support growth through strategic alliances, credit facilities and/or institutional equity financings with the goal of maximizing shareholder value. #T1D #IND #CellTherapy #Biotechnology
Press release
sernova.com
To view or add a comment, sign in
-
The sizzling antibody-drug conjugate (ADC) field is at the center of another major life sciences deal... READ ARTICLE FOLLOW #ProducedbyANP 🎬 #ANPharmaUpdate #Pharmanews #pharmamarketing #pharmamarketingnews
AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field
fiercepharma.com
To view or add a comment, sign in
-
Introducing Our Latest Expansion in Biomarker Analysis: Gyrolab® Mouse Cytokine Kits! 🐭 Fast and accurate measurement of 5 murine inflammatory cytokines: IL-4, IL-6, IL-10, IFN-gamma, and TNF-alpha By requiring small sample volumes, these ready-to-use kits optimize the amount of information achieved from each mouse sample. The Gyrolab Mouse Cytokine Kits have everything you need to run these assays using the Gyrolab Bioaffy™ 4000 CD, generating 96 datapoints with minimal hands-on time. Providing high sensitivity and robust assay performance, these kits are validated to achieve excellent specificity, dilution linearity, parallelism, and spike recovery. These Gyrolab Mouse Cytokine kits support biomarker studies in drug development programs from discovery to pre-clinical studies. https://lnkd.in/d67gwFjX #biomarkers #biomarker #immunoassay #drugdevelopment
Introducing Our Latest Expansion in Biomarker Analysis: Gyrolab® Mouse Cytokine Kits!
To view or add a comment, sign in
-
We're proud to support Oxford Global at #RNA Therapeutics & Delivery Europe. Our keynote is titled "Drug and target discovery with explainable AI" -- don't miss it! #drugdiscovery #explaianbleai #scientificAI #pharma #rnatherapeutics
We're super excited to announce the confirmed sponsors for RNA Therapeutics & Delivery Europe 2023! 🎉 📆 14-15 September 2023 | Berlin, Germany ➡️📖 Learn from key opinion leaders working to deliver RNA therapies for several therapeutic areas including infectious disease and cardiovascular disease: https://hubs.la/Q01YLsmC0 Sponsors include: Agilent Technologies, Abzu, NOF Europe, Takara Bio Inc., A&M STABTEST Labor für Analytik und Stabilitätsprüfung GmbH, Batavia Biosciences, Intravacc, Pfanstiehl, Inc., Advanced Instruments, LLC, BioSpring GmbH, Biotage, Cytiva, Denka Company Limited, Mabtech, Merck Group and Polypure AS! 🤝 ➡️🎫 Join RNA leaders, experts and distinguished scientists in Europe, delivering breakthrough research and technologies: https://hubs.la/Q01YLj070 Connect, Collaborate, Innovate. #FormulationSeries23 #RNATherapeutics #FormulationStrategies #DrugDelivery #mRNA
To view or add a comment, sign in
-
-
How many of you include clinically-relevant biomarkers in early drug discovery? In this blog you can learn how that could positively affect the clinical outcomes using ALS as an example of the current landscape. Share your thoughts in the comments #ALS #drugdiscovery #biomarkers
Are you aware of the recent failures of ALS drugs in clinical trials? In this blog we provide insights on the recent setbacks, discuss the increasing need for reliable biomarkers and a path forward with iPSC technology. Read the article here: https://lnkd.in/dTZYBDpv Key highlights: - These recent failures underscore a persistent issue in ALS research: the gap between preclinical success and clinical efficacy - Incorporating relevant biomarkers, like NfL, into the evaluation process can enhance the predictive power of preclinical models - iPSC technology enables studying the disease in a human context, with key biomarkers, providing more accurate predictions on disease mechanisms and drug responses. #news #ALS #stemcell #drugdiscovery #biomarkers #iPSCtechnology
To view or add a comment, sign in
-
-
Searching for groundbreaking drug discovery methods? Move into iPSC technology. Disease models that express relevant biomarkers for your target disease will help you identify the best drug candidates earlier. Our human in vitro models are built to express the most relevant biomarkers and to closely mimic human pathophysiology, revolutionizing early-stage drug development. From research labs to clinical trials, having the right biomarkers in your models holds the key to invaluable insights. Explore our expertise in leveraging crucial information through human iPSC-derived disease models. Learn more: https://lnkd.in/ewWgFYWA #BiomarkerDetection #EfficacyScreening #drugdevelopment
LinkedIn
To view or add a comment, sign in
-
Max just officially launched our first software product: ImmuneWatch DETECT! ImmuneWatch DETECT helps researchers from pharma, biotech and academia find the epitope specificity of their T-cell receptors (TCRs). This can be useful to them for numerous reasons ranging from monitoring therapy efficacy or using TCRs as biomarkers for diagnostic products to designing TCR-based therapeutics, or discovering new antigens related to autoimmune diseases for novel drug development. The bioinformatic tool is now available with a free licence for academic use and a fully featured premium version for industry users. We truly hope that it can help the whole community to gain more insights in their T cell responses. A big thank you to: 🫶 Our Early Access community who provided us valuable feedback in the last couple of months helping us achieve an average score of 4.3 out of 5 for ease of use. 🔍 The ImmuneWatch team for their dedication to make this happen. 🎤 Max van Houcke for his stellar demo on the #AIRRC7 conference today (The AIRR Community) Find out more: https://lnkd.in/eT7ERUxB
To view or add a comment, sign in
-
-
Are you aware of the recent failures of ALS drugs in clinical trials? In this blog we provide insights on the recent setbacks, discuss the increasing need for reliable biomarkers and a path forward with iPSC technology. Read the article here: https://lnkd.in/dTZYBDpv Key highlights: - These recent failures underscore a persistent issue in ALS research: the gap between preclinical success and clinical efficacy - Incorporating relevant biomarkers, like NfL, into the evaluation process can enhance the predictive power of preclinical models - iPSC technology enables studying the disease in a human context, with key biomarkers, providing more accurate predictions on disease mechanisms and drug responses. #news #ALS #stemcell #drugdiscovery #biomarkers #iPSCtechnology
To view or add a comment, sign in
-
More from this author
-
The Business of Biotech Highlights Bonum CEO John Mulligan & CBO Neela Patel
Bonum Therapeutics 7mo -
A BD Checklist: Best Practices for Partnering with Pharma - by Neela Patel
Bonum Therapeutics 9mo -
Developing the Next Generation of Targeted, Conditionally Active Cytokine Therapeutics - by Justin Killebrew
Bonum Therapeutics 1y